Redeye comments on Fluoguide presenting clinical trial data from its phase I/II trial in aggressive brain cancer. We judge the presented data further strengthen evidence around FG001’s efficacy in this indication and bode well for the coming top-line data readout later this year. We increase our estimated LoA for FG001 in aggressive brain cancer and raise our Base Case.